Roche Strengthens Its Bet Against the “Superbug”By Ion Jauregui – Analyst at ActivTrades
Zosurabalpin: A New Hope Against Antimicrobial Resistance
Swiss pharmaceutical giant Roche (SWX: ROG) has just taken a major step forward in the fight against bacterial resistance: its new antibiotic zosurabalpin is entering Phase 3 clinical trials. The co
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
11.1 EUR
8.80 B EUR
64.34 B EUR
688.71 M
About ROCHE I
Sector
Industry
CEO
Thomas Schinecker
Website
Headquarters
Basel
Founded
1896
ISIN
CH0012032048
Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics, and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
Roche vs. Novo Nordisk: Who will suffer the Weight Loss?Roche (ticker: ROG.SW) is losing ground on the stock due to the side effects of its new weight loss pill, CT-996, which is still in the testing phase. After a rally that boosted its shares 40% between May and September, the Swiss drugmaker has seen an 11% drop in its shares in September alone, inclu
Roche Analysis 6/26DISCLOSURE: as of 6/26 I have no open position in SIX:RO
Roche is a Swiss based pharmaceutical conglomerate with a diverse range of operations and brands. The company has a long history of profitability and high returns on investment.
Management Effectiveness: Roche has been around since 1896
Roche: Ready for 120% Growth?We're trying something with Roche here, where we think that we are currently in Wave (5), having recently completed Wave (4). This assessment is better visualized on the daily chart. Hence, we should maintain the 61.8% level for this Wave 4. Anything below would statistically be too low, while above
Hold it like a rock - Roche, what an opportunity.Hi, 1PERCENT here.
Roche Holding, a Swiss multinational biopharma company. It is like the Apple of biopharma.
There were only 3 pull backs greater than 30% in the history of the stock.
2002 ~ 2003: -45.33%
2006 ~ 2011: -52.40%
2014 ~ 2018: -30.24%
2022 ~ present: -44.89%
It is at the support z
Roche HoldingsThis is one of those companies you can't afford not to look into. Roche is one of the world's largest biotech companies and a global leader in pharmaceuticals and diagnostics. This leading position translates to strong market share, revenue, and profitability. The company operates across various seg
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
CHGCY5317644
Roche Holdings, Inc. 2.607% 13-DEC-2051Yield to maturity
7.08%
Maturity date
Dec 13, 2051
CHGCY4184535
Roche Holdings, Inc. 4.0% 28-NOV-2044Yield to maturity
6.03%
Maturity date
Nov 28, 2044
CHGCY3666852
Genentech, Inc. 5.25% 15-JUL-2035Yield to maturity
5.91%
Maturity date
Jul 15, 2035
CHGCY5766486
Roche Holdings, Inc. 5.218% 08-MAR-2054Yield to maturity
5.72%
Maturity date
Mar 8, 2054
CHGCY5766485
Roche Holdings, Inc. 5.218% 08-MAR-2054Yield to maturity
5.36%
Maturity date
Mar 8, 2054
CHGCY5317198
Roche Holdings, Inc. 2.076% 13-DEC-2031Yield to maturity
5.22%
Maturity date
Dec 13, 2031
CHGCY5766483
Roche Holdings, Inc. 4.985% 08-MAR-2034Yield to maturity
5.19%
Maturity date
Mar 8, 2034
CHGCY4391962
Roche Holdings, Inc. 7.0% 01-MAR-2039Yield to maturity
5.14%
Maturity date
Mar 1, 2039
CHGCY5698748
Roche Holdings, Inc. 5.593% 13-NOV-2033Yield to maturity
5.10%
Maturity date
Nov 13, 2033
CHGCY5885612
Roche Holdings, Inc. 4.592% 09-SEP-2034Yield to maturity
5.10%
Maturity date
Sep 9, 2034
CHGCY5766481
Roche Holdings, Inc. 4.909% 08-MAR-2031Yield to maturity
5.09%
Maturity date
Mar 8, 2031
See all ROCH bonds
Curated watchlists where ROCH is featured.
Related stocks
Frequently Asked Questions
The current price of ROCH is 279.5 EUR — it hasn't changed in the past 24 hours. Watch ROCHE HOLDING AG stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on VIE exchange ROCHE HOLDING AG stocks are traded under the ticker ROCH.
ROCH stock has risen by 0.47% compared to the previous week, the month change is a −1.62% fall, over the last year ROCHE HOLDING AG has showed a −1.45% decrease.
We've gathered analysts' opinions on ROCHE HOLDING AG future price: according to them, ROCH price has a max estimate of 485.59 EUR and a min estimate of 235.31 EUR. Watch ROCH chart and read a more detailed ROCHE HOLDING AG stock forecast: see what analysts think of ROCHE HOLDING AG and suggest that you do with its stocks.
ROCH reached its all-time high on May 7, 2025 with the price of 285.3 EUR, and its all-time low was 265.4 EUR and was reached on May 12, 2025. View more price dynamics on ROCH chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ROCH stock is 0.18% volatile and has beta coefficient of 1.15. Track ROCHE HOLDING AG stock price on the chart and check out the list of the most volatile stocks — is ROCHE HOLDING AG there?
Today ROCHE HOLDING AG has the market capitalization of 221.39 B, it has increased by 0.74% over the last week.
Yes, you can track ROCHE HOLDING AG financials in yearly and quarterly reports right on TradingView.
ROCHE HOLDING AG is going to release the next earnings report on Jul 24, 2025. Keep track of upcoming events with our Earnings Calendar.
ROCH earnings for the last half-year are 9.12 EUR per share, whereas the estimation was 8.94 EUR, resulting in a 1.98% surprise. The estimated earnings for the next half-year are 11.26 EUR per share. See more details about ROCHE HOLDING AG earnings.
ROCHE HOLDING AG revenue for the last half-year amounts to 32.60 B EUR, despite the estimated figure of 32.74 B EUR. In the next half-year revenue is expected to reach 33.49 B EUR.
ROCH net income for the last half-year is 2.15 B EUR, while the previous report showed 6.50 B EUR of net income which accounts for −66.96% change. Track more ROCHE HOLDING AG financial stats to get the full picture.
Yes, ROCH dividends are paid annually. The last dividend per share was 10.17 EUR. As of today, Dividend Yield (TTM)% is 3.73%. Tracking ROCHE HOLDING AG dividends might help you take more informed decisions.
ROCHE HOLDING AG dividend yield was 3.80% in 2024, and payout ratio reached 93.40%. The year before the numbers were 3.93% and 66.71% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of May 29, 2025, the company has 103.25 K employees. See our rating of the largest employees — is ROCHE HOLDING AG on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ROCHE HOLDING AG EBITDA is 22.37 B EUR, and current EBITDA margin is 35.81%. See more stats in ROCHE HOLDING AG financial statements.
Like other stocks, ROCH shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ROCHE HOLDING AG stock right from TradingView charts — choose your broker and connect to your account.